CoChat

Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease

Open access
Grimmer, Timo, Tholen, Susanne, Yousefi, Behrooz H., Alexopoulos, Panagiotis, Förschler, Annette, Förstl, Hans, Henriksen, Gjermund, Klunk, William E., Mathis, Chester A., Perneczky, Robert, Sorg, Christian, Kurz, Alexander, Drzezga, Alexander · 2010 · Biological Psychiatry
Cited by 101

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background Pittsburgh Compound B ([11C] PiB) is a specific positron emission tomography (PET) marker of cerebral amyloid deposits. Only few data have been published on in vivo longitudinal changes of amyloid load in Alzheimer’s disease (AD) patients, with conflicting results. Therefore, little is known about the factors that influence these changes. Methods A group of 24 patients with probable AD diagnosed by combining established clinical criteria with an AD-typical pattern in [18F] fluoro-deoxyglucose PET underwent [11C] PiB-PET examinations at baseline and after 24 months. The difference of amyloid load between the two examinations and the association with clinical and neurobiological variables was examined with a regions-of-interest approach and voxel-based analyses. Results Cerebral [11C] PiB uptake ratio increased significantly by an annual rate of 3.92%. Although the increase occurred in all parts of the neocortex, no increase was detected in the archipallium. The increase was gene-dose-dependent (analysis of variance p = .012) to the number of apolipoprotein E ε4 alleles. Progression of dementia symptoms was correlated to the [11C] PiB increase in numerous regions associated with cognition. Conclusions The results of this study indicate that a significant increase of amyloid deposition occurs in patients with AD during a relatively short interval of its clinical course. The rate of amyloid aggregation rate is closely associated with the apolipoprotein E genotype, which might be important for the evaluation of antiamyloid drug treatment effects. The present study further emphasizes the value of amyloid-plaque imaging as a marker of disease progression and as a potential surrogate marker to be used in antiamyloid drug trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2010.05.013

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 101

Metadata

Authors
Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., Sorg, C., Kurz, A., & Drzezga, A.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2010-11
Volume
68
Issue
10
Pages
879-884
ISSN
0006-3223 (ISSN-L)
OpenAlex
W1990143520
Cited by
101
References
14
FWCI
7.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease. https://app.cochat.ai/papers/10.1016/j.biopsych.2010.05.013
The paper
Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., Sorg, C., Kurz, A., & Drzezga, A. (2010). Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2010.05.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.